Evommune, Inc.
For the period ended Sep 30, 2025. Filed Dec 11, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Dec 11, 2025
EVMN$7.84+2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (unaudited)
(In thousands)
| Nine Months Ended | ||||
|---|---|---|---|---|
| September 30, | ||||
| 2025 · 2024 | ||||
| Cash flows from operating activities: | ||||
| Net loss | $ | (40,597) | $ | (46,082) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Stock-based compensation expense | 1,660 | 1,228 | ||
| Accretion of discount on short-term investments | (1,184) | (1,374) | ||
| Depreciation and amortization | 1,063 | 927 | ||
| Change in fair value of convertible preferred stock forward | (8,928) | — | ||
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses and other assets | (1,998) | (311) | ||
| Accounts payable | (4,688) | 3,652 | ||
| Accrued liabilities | (1,479) | 2,844 | ||
| Operating lease liabilities | (591) | (567) | ||
| Deferred revenue | (3,000) | — | ||
| Net cash used in operating activities | (59,742) | (39,683) | ||
| Cash flows from investing activities: | ||||
| Purchases of short-term investments | (38,775) | (45,675) | ||
| Maturities of short-term investments | 46,500 | 74,850 | ||
| Purchase of property and equipment | (131) | (88) | ||
| Net cash provided by investing activities | 7,594 | 29,087 | ||
| Cash flows from financing activities: | ||||
| Proceeds from issuance of convertible preferred stock, net of issuance costs | 65,228 | — | ||
| Proceeds from exercise of stock options | 6 | 2 | ||
| Payment of deferred offering costs | (874) | — | ||
| Principal payments of finance lease liability | (287) | (124) | ||
| Principal payments of financing obligation | (158) | (160) | ||
| Net cash provided by (used in) financing activities | 63,915 | (282) | ||
| Net increase (decrease) in cash, cash equivalents and restricted cash | 11,767 | (10,878) | ||
| Cash, cash equivalents and restricted cash - beginning of period | 16,463 | 29,232 | ||
| Cash, cash equivalents and restricted cash - end of period | $ | 28,230 | $ | 18,354 |
| Reconciliation of cash, cash equivalents, and restricted cash to the amounts reports within the balance sheets | ||||
| Cash and cash equivalents | $ | 26,818 | $ | 18,146 |
| Restricted cash | 1,412 | 208 | ||
| Total cash, cash equivalents, and restricted cash | $ | 28,230 | $ | 18,354 |
| Supplemental cash flow disclosures: | ||||
| Cash paid for interest | $ | 7 | $ | 28 |
| Deferred offering costs in accrued expenses | $ | 1,059 | $ | — |
| Non-cash investing and financing activities: | ||||
| Vesting of early exercised stock options | $ | 31 | $ | 39 |
| Assets acquired under finance leases | $ | — | $ | 1,032 |
| Operating lease liabilities arising from obtaining right-of-use assets | $ | 264 | $ | — |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.